Licensed clinic & professional formulary
PureVital logo
Formulary / GLP Weight Loss Vials / Tirzepatide
Tirzepatide — PureVital
PureVital
VialFeaturedIn stock

Strength

45mg /3ml

Total API

135 mg

Form

Vial

Brand

PureVital

GLP Weight Loss Vials

Tirzepatide

Dual GIP/GLP-1 agonist for advanced metabolic clinics

PV-TIRZEPATIDE-45MG3ML

Professional price

$299.99

View monograph

Tirzepatide engages both GIP and GLP-1 receptors, offering a dual-incretin approach used in many contemporary weight-management and metabolic programs under licensed supervision. Presentation: 45mg /3ml (Vial); total API 135 mg. For licensed clinics and practitioners.

  • Dual GIP/GLP-1 agonist for advanced metabolic clinics
  • Strength: 45mg /3ml
  • Total API: 135 mg
  • Vial presentation for licensed clinic programs
Licensed clinic formulary
Label-first SKU detail
Wholesale & bulk desk

PureVital Clinical Formulary — Strength & Volume updates April 2026

Mechanism themes

Receptor and pathway context written for clinic teams.

Clinic-use references

Titration and presentation notes — not patient prescriptions.

Safety & regulatory

Precautions, interactions, and status framing in one monograph.

Clinical monograph

Professional product details

Dual GIP/GLP-1 agonist for advanced metabolic clinics. Structured for licensed clinics — mechanism, clinic-use themes, safety, and package clarity in one place.

Compound family

tirzepatide

Overview

Tirzepatide engages both GIP and GLP-1 receptors, offering a dual-incretin approach used in many contemporary weight-management and metabolic programs under licensed supervision.

Label-first clinic supply presentation

Contents of the package

What arrives for this PureVital SKU

  • 1 × 45mg /3ml vial presentation
  • Active listing: Tirzepatide
  • Total API (label): 135 mg
  • SKU PV-TIRZEPATIDE-45MG3ML
  • For parenteral clinic use as directed by the licensed prescriber
  • PureVital professional clinical formulary supply

About Tirzepatide

Dual agonism can deliver robust appetite and glycemic effects in appropriate patients. PureVital stocks vial, pen, and sublingual presentations so clinics can match route to adherence.

Mechanism of action

LigandReceptorcascadeCliniceffect
  • GIP receptor activity supports metabolic signaling alongside GLP-1
  • GLP-1 pathway contributes to satiety and slowed gastric emptying
  • Combined incretin tone is used in structured titration programs

Clinic use & titration (professional reference)

01

Start low

02

Assess GI

03

Escalate

04

Maintain

Programs commonly escalate weekly doses in steps as tolerated. Confirm concentration and pen/vial markings before each dispense.

  • Assess GI tolerability before each escalation
  • Coordinate nutrition support during rapid weight-change phases
  • Document indication, consent, and monitoring in the clinic chart

Adverse reactions & precautions

  • Class-typical GI adverse effects during titration
  • Monitor for warning symptoms consistent with incretin labeling
  • Review concomitant oral drug timing given delayed gastric emptying

Regulatory context

Branded tirzepatide is FDA-approved for labeled indications. Alternative clinic presentations require compliant sourcing and professional dispensing practices.

Educational formulary information for licensed clinics and practitioners only. PureVital presents professional supplement / wellness formulary items — not regular medicines. Final presentation choice, titration, and monitoring remain clinical decisions. Not intended to diagnose, treat, cure, or prevent any disease.

Continue browsing

Related formulary items

Same category presentations clinics often review together.

View GLP Weight Loss Vials →